Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-07	US$3.570	+0.28%	19,844
26-08-06	US$3.560	+0.28%	4,905
26-08-05	US$3.550	+1.14%	39,997
26-08-04	US$3.510	+0.57%	6,373
26-08-03	US$3.490	+1.45%	5,187

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 16:00:00 2026-08-07 EDT			5-day change	1st Jan Change
3.570 ^USD	+0.28%		+3.78%	+181.10%

08-04	Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-14	Cyclerion Therapeutics, Inc. announced that it has received $200 million in funding	CI

Market Cap	15.14M 13.1M 12.23M 11.22M 21.1M 1.44B 21.44M 143M 56.32M 722M 56.86M 55.61M 2.39B	P/E 2026 *	-2.98x	P/E 2027 *	-3.61x
Enterprise Value	15.14M 13.1M 12.23M 11.22M 21.1M 1.44B 21.44M 143M 56.32M 722M 56.86M 55.61M 2.39B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	77.51%	Yield 2026 *	-	Yield 2027 *	-

08-04	Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-14	Cyclerion Therapeutics, Inc. announced that it has received $200 million in funding	CI
05-12	Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-06	Top Premarket Decliners	MT
04-01	Top Midday Gainers	MT
04-01	Cyclerion Therapeutics, Inc., Korsana Biosciences, Inc. - M&A Call
04-01	Cyclerion Therapeutics and Korsana Biosciences announce merger agreement	RE
03-31	Korsana Biosciences, Inc. entered into a definitive merger agreement to acquire Cyclerion Therapeutics, Inc. from a group of shareholders for approximately $270 million in a reverse merger transaction.	CI
03-31	Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Cyclerion Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-17	Cyclerion Therapeutics announces progress toward Cyc-126 phase 2 proof-of-concept study with FDA feedback	RE
02-17	Cyclerion Therapeutics, Inc. Receives Positive Written Regulatory Feedback and Responses from the FDA on CYC-126's Phase 2 POC study in TRD and Its Path to Potential Regulatory Approval	CI
02-17	Cyclerion Therapeutics, Inc. Announces Formation of Clinical Advisory Board	CI

21-10-20	CYCLERION THERAPEUTICS : Truist Securities Starts Cyclerion Therapeutics at Buy with $14 Price Target	MT
21-09-27	CYCLERION THERAPEUTICS : Cantor Fitzgerald Starts Cyclerion Therapeutics at Overweight with $7 Price Target	MT
21-09-24	CYCLERION THERAPEUTICS : Cantor Fitzgerald Initiates Cyclerion Therapeutics at Overweight Rating With $7 Price Target	MT

Cyclerion Therapeutics, Inc. Stock

Stocks

CYCN

US23255M2044

Biotechnology & Medical Research

Valuation: Cyclerion Therapeutics, Inc.

Chart: Cyclerion Therapeutics, Inc.

Latest news : Cyclerion Therapeutics, Inc.

Last Transcript: Cyclerion Therapeutics, Inc.

Analysts' recommendations: Cyclerion Therapeutics, Inc.

Press Releases: Cyclerion Therapeutics, Inc.

News in other languages: Cyclerion Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Cyclerion Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

08-04	Cyclerion Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
04-01	Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement	BU
02-17	Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board	AQ
01-05	Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression	AQ
11-12	Cyclerion Therapeutics : Amendment to Annual Report (Form 10-K/A)	PU

1 day	+0.28%
1 week	+3.78%
Current month	+3.78%
1 month	+2.59%
3 months	+13.33%
6 months	+224.55%
Current year	+181.10%

1 week	3.37	3.71
1 month	3.36	3.97
Current year	1.03	8.48
1 year	1.03	8.48
3 years	1.03	9.47
5 years	1.03	72.45
10 years	1.03	457

Manager	Title	Age	Since
Regina Graul CEO	Chief Executive Officer	49	2024-08-06
Rhonda Chicko DFI	Director of Finance/CFO	60	-

Director	Title	Age	Since
Peter Hecht BRD	Director/Board Member	62	2019-03-31
Errol de Souza CHM	Chairman	72	-
Steven Hyman BRD	Director/Board Member	73	2022-07-24

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/16/26	Peter Hecht	Conversion	Director	351,037	8.1065%
7/16/26	Peter Hecht	Conversion	Director	-351,037	100.0000%
8/7/25	Rhonda Chicko	Free	Chief Financial Officer	25,000	0.9225%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYCLERION THERAPEUTICS, INC.	+0.28%	+3.78%	+51.59%	+7.85%	15.14M
WUXI APPTEC CO., LTD.	+8.49%	+20.55%	+69.74%	+109.30%	68.12B
ARGENX SE	+1.25%	+2.44%	+32.55%	+72.63%	55.18B
INSMED INCORPORATED	-1.09%	+32.96%	+19.95%	+499.45%	28.63B
BIONTECH SE	+2.72%	+3.41%	-15.88%	-4.90%	23.53B
WUXI BIOLOGICS (CAYMAN) INC.	+10.83%	+18.38%	+52.76%	+4.58%	23.99B
GENMAB A/S	+6.50%	+7.56%	+38.20%	-21.33%	18.45B
PHARMAESSENTIA CORPORATION	-3.88%	+16.98%	+199.30%	+354.30%	15.83B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.20%	+11.51%	+34.94%	+681.88%	16.44B
EXELIXIS, INC.	+3.58%	+1.96%	+44.61%	+167.01%	13.4B
Average	+3.49%	+10.89%	+52.78%	+187.08%	26.36B
Weighted average by Cap.	+4.36%	+13.09%	+49.48%	+168.48%

	2026 *	2027 *
Net sales	-	-
Net income	-12M -10.38M -9.69M -8.89M -16.73M -1.14B -16.99M -114M -44.64M -572M -45.06M -44.08M -1.89B	-14.8M -12.8M -11.96M -10.97M -20.63M -1.41B -20.96M -140M -55.05M -706M -55.58M -54.36M -2.33B
Net Debt	-	-